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Edited by Henrik DohlmanReliable measurement of ligand binding to cell surface re-
ceptors is of outstanding biological and pharmacological
importance. Resonance energy transfer–based assays are
powerful approaches to achieve this goal, but the currently
available methods are hindered by the necessity of receptor
tagging, which can potentially alter ligand binding properties.
Therefore, we developed a tag-free system to measure ligand‒
receptor interactions in live cells using the Gaussia luciferase
(GLuc) as a bioluminescence resonance energy transfer donor.
GLuc is as small as the commonly appliedNanoluciferase but has
enhanced brightness, and its proper substrate is the frequently
used coelenterazine. In our assay, bystander bioluminescence
resonance energy transfer is detected between a GLuc-based
extracellular surface biosensor and fluorescent ligands bound to
their unmodified receptors. The broad spectrum of applications
includes equilibrium and kinetic ligand binding measurements
for both labeled and competitive unlabeled ligands, and the assay
can be utilized for different classes of plasma membrane re-
ceptors. Furthermore, the assay is suitable for high-throughput
screening, as evidenced by the identification of novel α1 adren-
ergic receptor ligands. Our data demonstrate that GLuc-based
biosensors provide a simple, sensitive, and cost-efficient plat-
form for drug characterization and development.
The superfamily of plasma membrane (PM) receptors con-
sists of a diverse range of signaling proteins, such as G protein–
coupled receptors (GPCRs), tyrosine kinase receptors, enzyme-
linked receptors, nutrient receptors, or ion channels. In addi-
tion to their important role in sensing environmental signals,
their altered function is commonly reported in a wide array of
pathological conditions. Accordingly, most of our currently
prescribed drugs target cell surface receptors (1). A growing
number of evidences indicates that characteristics of drug‒re-
ceptor interaction may profoundly shape the pharmacological
outcome. In addition to affinity and efficacy, kinetic ligand pa-
rameters were also shown to be decisive factors for the clinical
action of drugs. Association and dissociation rate constants (kon‡ These authors contributed equally to this work.
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BY license (http://creativecommons.org/licenses/by/4.0/).and koff) of drugs, by defining ligand residence time, have been
linked to various drug properties, such as duration of action,
efficacy, or occurrence of side effects (2–7). Therefore, the
proper characterization of drug‒receptor interactions represents
a major task for drug development. Although various techniques
with different advantageous properties are available, they all
have serious drawbacks (8). For example, traditional radioligand
binding measurements are ponderous and burdensome, espe-
cially in case of kinetic binding measurements, and the strict
rules required for handling radioactive compounds limit their
use. In contrast, fluorescence-based approaches are not hin-
dered by the practical limitations surrounding the use of
radioactivity but often suffer from low signal-to-noise ratio due
to the autofluorescence of biological samples. By overcoming
these limitations, resonance energy transfer–based measure-
ments have revolutionized the application of fluorescent ligands
in binding measurements (9–13). In these assays, resonance
energy transfer is detected between a fluorescent or luminescent
donor attached to a receptor and a fluorophore conjugated to a
receptor ligand. Since the efficiency of resonance energy transfer
strongly depends on the molecular proximity, a condition that is
met during ligand binding, the signal-to-noise ratio is greatly
enhanced. Time-resolved Förster resonance energy transfer
(FRET) and bioluminescence resonance energy transfer (BRET)
have been successfully used to detect ligand binding of various
receptors for equilibrium and kinetic measurements as well.
However, these methods require the covalent labeling of the
target protein, which may substantially alter the receptor func-
tion. Furthermore, the high cost of some substrates may limit
their use in high-throughput applications. Therefore, there is a
continuous need for new and surpassing assays to assess ligand‒
receptor binding. Here we report a novel BRET-based approach
to measure ligand binding of cell surface receptors. The method
is cost-effective, does not need receptor modification, and is also
applicable in high-throughput drug screenings.Results
Gaussia luciferase is a small and bright luciferase
Since N-terminal receptor tagging with naturally non-
secreted and high-molecular-weight luciferases (such asJ. Biol. Chem. (2021) 296 100366 1
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Detection of ligand binding of unlabeled receptors with GLucRenilla luciferase) induces endoplasmic retention and
impaired PM expression of several receptors, it was not
possible to study receptor‒ligand binding with BRET for a
long time (8). This limitation has been overcome by the
development of the small luciferase NanoLuciferase (Nano-
Luc) (14), a variant of the naturally secreted luciferase of the
deep-sea shrimp Oplophorus gracilirostris, which has made
BRET suitable to detect ligand binding of NanoLuc-tagged
receptors. However, the high cost of furimazine, the proper
substrate of NanoLuc, seriously hinders the widespread
application, especially in high-throughput experiments.
Therefore, we aimed to establish a system using an alternative
coelenterazine-utilizing luciferase that is also secreted natu-
rally; thus, it may not induce incorrect folding of proteins
tagged on the extracellular side. The luciferase of the marine
copepod Gaussia princeps (Gaussia luciferase, GLuc) has the
same molecular weight as NanoLuc (19 kDa), but its appro-
priate substrate is a natural substance, the native coelenter-
azine (Fig. 1A) (15). Since GLuc is rapidly inactivated, we used
a mutant of GLuc (GLucM23) (16), which emits light sub-
stantially longer and was shown to be even 10-fold brighter
than the wildtype enzyme. First, we compared the properties of
GLuc and NanoLuc with constructs that label the extracellularFigure 1. GLuc is a bright alternative to NanoLuc. A, general characteristic
bioluminescent and fluorescent images show that the PM-targeted constructs
experiments; the scale bars represent 10 μm. D, temporal decay of biolumine
concentration was not provided by Promega, the suggested dilution in proto
substrates, as indicated, and luminescence was continuously measured for 60
assessed with one phase decay curve fitting. E, peak luminescence of GLuc
trations: native coelenterazine (coel; 50, 15, 5, 1.5, and 0.5 μM), coelenterazine
(DBC; 5 μM). In D and E, the experiments were performed with the GLuc–PM–V
was normalized to Venus fluorescence. Scatter dot plots with bars are shown, d
3. F, emission spectra of GLuc and NanoLuc. GLuc–PM and NanoLuc–PM constr
(coel; 5 μM) for GLuc and coelenterazine h (coelenterazine h; 5 μM) or furima
iments. GLuc, Gaussia luciferase; NanoLuc, NanoLuciferase; PM, plasma memb
2 J. Biol. Chem. (2021) 296 100366surface of the PM (GLuc‒PM and NanoLuc‒PM) by fusing
them to a transmembrane domain. We also created versions of
the constructs that were intracellularly tagged with Venus to
perform expression-normalized comparisons (Fig. 1B). Using
bioluminescent and fluorescent image acquisition, we verified
that all constructs had proper PM localization (Fig. 1C). As
shown in Figure 1, D and E, GLuc was found to have extreme
brightness, was even brighter than NanoLuc, and both lucif-
erases produced long-lasting (glow-type) luminescence
(Fig. 1D). We tested the effect of different substrates in mul-
tiple concentrations. In agreement with previous studies, GLuc
was the brightest when native coelenterazine was used (15, 16).
The GLuc-emitted luminescence was already sufficiently
detectable in the presence of 5 μM coelenterazine; therefore,
this concentration was used in the experiments. Similar to
previous reports (17, 18), we found that NanoLuc efficiently
utilizes some other coelenterazine derivatives as well, such as
2-deoxycoelenterazine (coelenterazine h). Although coe-
lenterazine h was shown to be inferior as a substrate of
NanoLuc compared with furimazine, it still induced sufficient
brightness to perform BRET measurements in our setup. We
compared the emission spectra of GLuc and NanoLuc, and the
emission of the former was right-shifted by approximatelys of NanoLuc and GLuc. B, schematic structures of the used constructs. C,
have proper PM localization. Representative images from three independent
scence of NanoLuc and GLuc. Furimazine (fur; used in 1:200 dilution, stock
col #TM439 is 1:500) or native coelenterazine (coel; 50 μM) was added as
min, n = 3, data are mean ± SD. τNanoLuc = 12.2 min and τGLuc = 9.5 min
and NanoLuc upon treatment with different substrates in distinct concen-
h (coel h; 50, 15, 5, 1.5, and 0.5 μM), furimazine (fur; 1:200) and DeepBlueC
enus and NanoLuc–PM–Venus constructs, and the measured luminescence
ata are mean + SD. ****p < 0.0001, one-way ANOVA, Tukey post hoc test, n =
ucts were used for the measurements. Substrates were native coelenterazine
zine (fur; 1:200) for NanoLuc. Data are means of three independent exper-
rane.
Figure 2. Measurement of ligand binding of tagged or unmodified receptors in equilibrium. A, schematic representation of the receptor–ligand BRET
measurements. Binding of a fluorescent ligand to its luciferase (Luc)-tagged receptor results in the molecular proximity of the BRET donor and acceptor
molecules, which promotes resonance energy transfer and increase of the BRET signal. A competitor unlabeled ligand prevents the receptor binding of the
fluorescent ligand, thus the specific BRET signal does not develop. B and C, competitive binding curves of NanoLuc–AT1R (B) and GLuc–AT1R (C). One
micromolar TAMRA–AngII and increasing concentrations of candesartan were applied. Red and brown two-headed arrows indicate the specific (candesartan-
sensitive) and the nonspecific (candesartan-insensitive) signal, respectively. Two site competitive binding curves were fitted, B: IC50_Hi = 520 pM, IC50_Lo =
1 nM; n = 4. C: IC50_Hi = 207 pM, IC50_Lo = 1.3 nM; n = 3. D, concentration dependency of TAMRA–AngII binding to GLuc–AT1R. The BRET ratio was measured
in GLuc–AT1R–expressing cells upon treatment of increasing concentrations of TAMRA–AngII. Nonspecific signal was assessed by cotreatment of 30 μM
Detection of ligand binding of unlabeled receptors with GLuc
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Detection of ligand binding of unlabeled receptors with GLuc20 nm (Fig. 1F), which may be beneficial for the excitation of
red-emitting acceptors.
GLuc is suitable for ligand binding applications
To test the performance of GLuc in BRET assays, we
measured receptor‒ligand BRET in a similar manner as it
was described in a previous study with NanoLuc (Fig. 2A)
(12). We expressed GLuc- or NanoLuc-tagged AT1 angio-
tensin receptor (AT1R) in HEK 293T cells as BRET donors
and treated them with red fluorophore–conjugated angio-
tensin II (TAMRA‒AngII) as BRET acceptor for 2 h at room
temperature to reach equilibrium binding (Fig. 2, B and C).
In both cases, the binding of TAMRA‒AngII to the tagged
receptors resulted in an increase of the BRET signal, as the
molecular proximity between the donor and the acceptor
caused resonance energy transfer. The increase of the BRET
ratio was higher with GLuc‒AT1R, for which a possible
explanation could be the greater overlap between the exci-
tation spectrum of TAMRA and the emission spectrum of
GLuc than that of NanoLuc. The specificity of the signal was
verified by competitive ligand binding measurements. The
competitive AT1R antagonist candesartan prevented a great
portion of the BRET signal, proving that this part of the
signal originated from specific interaction between
TAMRA‒AngII and AT1R. The remaining nonspecific signal
reflects random collisions between the donor and acceptor
molecules (bystander BRET), whose amplitude is linearly
proportional to the acceptor concentration. Accordingly,
increasing concentrations of TAMRA‒AngII elevated the
nonspecific signal linearly, whereas the specific binding was
saturable (Fig. 2D). To avoid possible receptor
internalization–related changes in the signal, we always
overexpressed an internalization inhibitor protein, the
dominant negative form of dynamin2A (DN-Dyn). We
confirmed that its application does not disturb the ligand
binding properties of the receptor (Fig. S1, A and B). We also
tested GLuc in receptor‒ligand BRET measurements for
another GPCR, the α1A adrenergic receptor (α1AAR) (Fig. 2,
E and F). The green-emitting fluorescent BODIPY FL‒candesartan. Specific signal was calculated by subtracting the nonspecific sig
curves were fitted (KD_Hi = 1.016 μM and KD_Lo = 26.42 μM), n = 4. E, concen
specific, and nonspecific one site binding curves were fitted (KD = 61.13 nM)
150 nM, was used as the labeled ligand; prazosin, A61603, and carvedilol wer
were fitted on the points of the ɑ1AAR antagonists (prazosin, Ki = 4.17 nM and c
points of the ɑ1AAR agonist A61603 (Ki_Hi = 32.5 pM, Ki_Lo = 187 nM), n = 6. G
cotransfected with untagged receptors and cell surface–targeted luciferase
enrichment at the PM, which results in the increase of bystander BRET between
receptor prevents the signal. H and I, competitive binding curves of untagged
ments and curve fitting were used as in B and C; data are presented as the
candesartan. H: 100% = 0.0062 ± 0.0017, IC50_Hi = 1.29 nM, IC50_Lo = 19.6 nM; n
K, BRET change upon TAMRA–AngII treatment with NanoLuc–PM (J) or GLuc
cotransfected with AT1R or pcDNA3.1, 1 μM TAMRA–AngII, 30 μM candesartan
0.0029, unpaired, two-tailed t test. L, concentration dependency of TAMRA–An
curve fitting were used as in D (KD_Hi = 287 nM and KD_Lo = 18.46 μM), n = 4. M,
PM. Two site competitive binding curves were fitted, IC50_Hi = 105 nM for Ang
concentration dependency of BODIPY FL–prazosin binding to ɑ1AAR measured
fitted (KD = 46.63 nM), n = 4. O, competitive binding curves of prazosin, A6160
applied as in F. Ki = 2.72 nM was for prazosin, Ki = 43.8 nM was for carvedilol, K
with mean + SD are shown in J and K, and data are mean ± SD in the other pa
compounds at room temperature. BRET, bioluminescence resonance energy t
fluorophore–conjugated angiotensin II.
4 J. Biol. Chem. (2021) 296 100366prazosin was applied as the labeled ligand, the α1AAR
antagonist prazosin and carvedilol or the α1AAR agonist
A61603 were used as unlabeled ligands. Again, the ligand
binding of the tagged receptor could be detected with GLuc.
The tracer ligand was displaced by all α1AAR ligands, rep-
resenting that binding of any orthosteric ligand can be
measured.
NanoLuc‒PM and GLuc‒PM biosensors allow the detection of
ligand binding of unmodified GPCRs
It must be emphasized that the phenomenon of bystander
BRET not only denotes a background signal but can also be
beneficially exploited. Bystander BRET measurements are
widely used to detect enrichment of a protein in a particular
compartment, where a compartment-targeted molecule and
the protein of interest are labeled with BRET partners. The
labeling can even be indirect by tagging an interaction
partner of the protein, which has the advantage that no
molecular modification of the protein under investigation is
required. Using bystander BRET, cellular redistribution of
proteins, such as receptor internalization and β-arrestin
recruitment, or lipid levels in the PM were previously
successfully monitored (19–23). In these experiments, the
acceptor accumulation in the donor’s proximity results in
the elevation of the BRET signal. We applied a strategy
based on similar principles to assess ligand binding of un-
modified receptors. Instead of measuring BRET between
luciferase-tagged receptors and their fluorescent ligands
(“receptor‒ligand BRET”), we detected bystander BRET
between luciferase-labeled PM and fluorescent ligands
bound to their receptors (“PM‒ligand BRET”) (Fig. 2G). We
coexpressed untagged AT1R with GLuc‒PM or NanoLuc‒
PM constructs that label the extracellular side of the PM
(Fig. 2, H and I). Treatment of cells with TAMRA‒AngII
induced an increase of the BRET signal between the PM-
targeted donor and TAMRA‒AngII. This signal originated
from two types of bystander BRET. A significant portion of
the signal could be prevented by the AT1R antagonist
candesartan, showing that this signal reflects the specificnal from the total signal. Two site-specific, total, and nonspecific binding
tration dependency of BODIPY FL–prazosin binding to GLuc–ɑ1AAR. Total,
, n = 4. F, competitive binding curves of GLuc–ɑ1AAR. BODIPY FL–prazosin,
e added in increasing concentrations. One site competitive binding curves
arvedilol, Ki = 62.7 nM); two site competitive binding curve was fitted on the
, schematic representation of the PM–ligand BRET measurements. Cells are
(Luc-biosensor). Fluorescent ligand binding to the receptor leads to its
the luciferase and the fluorescent ligand. Binding of unlabeled ligand to the
AT1R obtained with NanoLuc–PM (H) or GLuc–PM (I). Similar ligand treat-
percentage of the ΔBRET ratio induced by TAMRA–AngII in the absence of
= 4. I: 100% = 0.0168 ± 0.004, IC50_Hi = 1.24 nM, IC50_Lo = 248 μM; n = 4. J and
–PM (K) in the presence or absence of receptor coexpression. Cells were
, or vehicle treatments were applied, as indicated, n = 4. *p = 0.0173, **p =
gII binding to AT1R measured with GLuc–PM. Similar ligand treatments and
AT1R binding of agonists with distinct functional effects assessed with GLuc–
II and IC50_Hi = 1.28 μM for SII, IC50_Lo fit values were ambiguous, n = 3. N,
with GLuc–PM. Total, specific, and nonspecific one site binding curves were
3, and carvedilol to ɑ1AAR assessed with GLuc–PM. Similar curve fitting was
i_Hi = 94.8 pM and Ki_Lo = 348.8 nM was for A61603, n = 4. Scatter dot plots
nels. Measurements were performed after 2-h incubation with the indicated
ransfer; GLuc, Gaussia luciferase; PM, plasma membrane; TAMRA‒AngII, red
Detection of ligand binding of unlabeled receptors with GLucinteraction between TAMRA‒AngII and untagged AT1R,
which caused the enrichment of TAMRA‒AngII at the PM.
Accordingly, this signal was absent when no receptor was
expressed (Fig. 2, J and K). The candesartan-insensitive part
of the signal was caused by the other (nonspecific) type of
bystander BRET (Fig. 2L), which is due to random collisions
between PM–tagged luciferases and unbound acceptor-
conjugated ligands. This candesartan-insensitive signal is
similar and equally high as in receptor‒ligand BRET mea-
surement (see Fig. 2, D and L). PM‒ligand BRET, in com-
parison with receptor‒ligand BRET, showed lower
amplitude of the specific signal (ΔBRET values of the
different setups are shown in Fig. 2, B, C, J, and K). This was
in agreement with the fact that resonance energy transfer is
greatly sensitive to the distance between donor and
acceptor molecules, which is larger when the PM is labeled
and not the target receptor. Remarkably, the half-maximal
inhibitory concentration of candesartan for the high-
affinity binding site (IC50_Hi) was significantly lower in the
case of the receptor‒ligand BRET than that of the PM‒
ligand BRET (Fig. S1, C and D). Accordingly, the dissocia-
tion constant of TAMRA‒AngII for the high-affinity bind-
ing site (KD_Hi) of the untagged receptor was smaller than
the KD_Hi for the GLuc-labeled receptor (Fig. 2, D and L),2AR, GLuc‒PM + 
300 nM BODIPY‒propranolol
D1R, GLuc‒PM + 
300 nM BODIPY‒S








































Figure 3. Application of GLuc–PM to assess ligand binding of multiple cell
(A, n = 5), of SCH 23390 to D1R (B, n = 3), of angiotensin II (AngII) to AT2R (C, n =
TfR (E, n = 3). In A–E, cells were cotransfected GLuc–PM with the examined rec
propranolol, 300 nM BODIPY FL‒SKF83566, 1 μM TAMRA‒AngII, 300 ng/ml biot
Fluor 488–conjugated human transferrin). Two-hour incubation was made on
TfR, the BRET ratio was normalized to treatment of transferrin without fluoresc
ratio induced by the treatment with fluorescent ligand without unlabeled ligan
(D), and 0.6519 ± 0.0344 (E) values were 100%). One site competitive binding c
pg/l (D), and 4.54 μg/l (E). β2AR, β2 adrenergic receptor; AT2R, AT2 angiotensin r
fluorophore–conjugated angiotensin II.demonstrating that receptor tagging altered the ligand
binding properties of the receptor. These results are in good
agreement with previous studies showing altered ligand
binding properties of AT1R upon N-terminal modification
(24, 25) and suggest that, although receptor‒ligand BRET is
a sensitive approach to detect ligand binding, the results
obtained with this method should be interpreted cautiously.
Since we achieved larger BRET signal changes with GLuc
than with NanoLuc in our system (compare Fig. 2, H with I
and Fig. 2, J with K), only GLuc BRET measurements were
performed in the further experiments. In principle, a ligand
binding assay should be able to detect the binding of any
orthosteric ligands regardless of their functional effects. In
accordance, we were able to determine the binding of both
the high-affinity full agonist angiotensin II (AngII) and the
low-affinity β-arrestin‒biased agonist [Sar1,Ile4,Ile8]-angio-
tensin II (SII) (26) with our assay (Fig. 2M).
We also measured the ligand binding of α1AAR with the
PM‒ligand BRET setup (Fig. 2, N and O). With this approach,
we were able to measure the competition binding of all three
unlabeled ligands, and no significant shift of competition
binding curves was observed compared with GLuc‒α1AAR,
suggesting that the effect of N-terminal receptor tagging on
receptor conformation may vary between GPCRs.KF83566
AT2R, GLuc‒PM + 
1 M TAMRA‒AngII






























surface receptor classes. Competitive binding curves of ICI118,551 to β2AR
5), of epidermal growth factor (EGF) to EGFR (D, n = 4), and of transferrin to
eptor, and the indicated labeled ligands were used (300 nM BODIPY FL‒(S)-
inylated EGF conjugated to Alexa Fluor 488 streptavidin, or 100 μg/ml Alexa
ice for β2AR and D1R, and at room temperature for the other receptors. For
ent ligand. Data are mean ± SD, expressed as the percentage of the ΔBRET
d (0.0142 ± 0.07 (A), 0.0262 ± 0.0023 (B), 0.0119 ± 0.0016 (C), 0.0186 ± 0.0057
urves were fitted. IC50 values were 9.84 nM (A), 1.07 nM (B), 479 nM (C), 15.8
eceptor; GLuc, Gaussia luciferase; PM, plasma membrane; TAMRA‒AngII, red
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Figure 4. Measurement of kinetic ligand parameters using GLuc. Left panels, kinetic receptor–ligand BRET measurements; right panels, kinetic PM–ligand
BRET measurements. A, dissociation kinetics of BODIPY FL–prazosin. After 15-min treatment with 150 nM BODIPY FL–prazosin, the ligand was washed out,
and the decline of the BRET ratio was followed. Prazosin was added to prevent rebinding. One phase exponential decay curves were fitted, koff of BODIPY
FL–prazosin was 1.84 × 10−3 s−1 for GLuc–ɑ1AAR, and koff was 1.33 × 10
−3 s−1 for ɑ1AAR assessed with GLuc–PM, n = 3. B, kinetics of association and
competitive ligand binding to ɑ1AAR. Cells were treated with 150 nM BODIPY FL–prazosin and increasing concentrations of prazosin (Praz) simultaneously.
kon of BODIPY FL–prazosin was 3.86 × 10
4 s−1M−1 for GLuc–ɑ1AAR, and kon was 3.22 × 10
4 s−1 for ɑ1AAR assessed with GLuc–PM. Prazosin kon and koff values
were 2.38 × 106 s−1M−1 and 3.51 × 10−3 s−1 for GLuc–ɑ1AAR, while they were 1.7 × 10
6 s−1M−1 and 2.55 × 10−3 s−1, respectively, for ɑ1AAR determined with
GLuc–PM, n = 5. C, dissociation kinetics of TAMRA–AngII. Cells were treated with 1 μM TAMRA–AngII for 15 min, then TAMRA–AngII was washed out and
BRET was measured in real time. Candesartan was applied to prevent rebinding. One phase exponential decay curves were fitted, koff of TAMRA–AngII was
Detection of ligand binding of unlabeled receptors with GLuc
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Detection of ligand binding of unlabeled receptors with GLucWe tested if the amplitude of the specific signal correlates
with the amount of the receptor DNA transfected (Fig. S2). We
found a positive correlation for both AT1R and α1AAR, sug-
gesting that a high level of receptor expression is advantageous
for good signal-to-noise separation.
PM‒ligand BRET using GLuc‒PM as a general approach for
ligand binding measurement of multiple families of cell
surface receptors
Theoretically, our PM‒ligand BRET system could be uti-
lized for ligand binding detection of any cell surface receptors,
if an appropriate fluorescent ligand is available. The approach
is quick and easy, as it requires only the coexpression of the
GLuc‒PM extracellular surface biosensor and the unmodified
receptor, and no further protein fusion procedure is needed.
First, we adjusted our system to other GPCRs. We could
detect the binding of BODIPY FL‒propranolol to the β2
adrenergic receptor (β2AR). Of interest, we found a consis-
tent increase of the BRET ratio at low concentrations of the
β2AR inverse agonist ICI118,552 instead of the expected
drop in the signal (Fig. S3). We speculated that the 2-h in-
cubation with the drug at room temperature may induce cell
responses, for example, receptor externalization, which
could influence the ligand binding results; therefore, we
performed incubations on ice. Accordingly, we got regular
competition binding curves (Fig. 3A). We could also suc-
cessfully examine the ligand binding of the D1 dopamine
receptor (D1R) or the AT2 angiotensin receptor (AT2R)
(Fig. 3, B and C). A study of the latter with our assay could be
especially useful in drug screening applications, because
AT2R cannot be investigated with receptor signaling assays,
as it does not signal in heterologous expression systems (27).
It is interesting that AT2R had a TAMRA‒AngII affinity
approximately two orders of magnitude higher than that of
AT1R (Fig. S4), which explains the observed relatively higher
IC50 of AngII to AT2R.
We also performed experiments with non-GPCR cell sur-
face receptors. We examined the epidermal growth factor re-
ceptor (EGFR), a prototypical tyrosine kinase receptor
(Fig. 3D), and the transferrin receptor (TfR), as an example of
cell surface nutrient receptors (Fig. 3E). In both cases, we
could detect the specific binding of the Alexa488-conjugated
ligands to their receptors, which was prevented by unlabeled
ligands. These results show that PM‒ligand BRET using GLuc
is a versatile tool for ligand binding measurement of cell sur-
face receptors.
Real-time kinetic detection of ligand binding using GLuc BRET
A major advantage of resonance energy transfer–based
ligand binding assays is the ability to detect ligand binding in0.04046 s−1 for GLuc–AT1R, and koff was 0.01731 s
−1 for AT1R assessed with G
association curves were fitted to calculate kon, kon of TAMRA–AngII was 1.15 × 1
with GLuc–PM, n = 3. E, kinetics of competitive binding to AT1R. Cells were sim
indicated concentrations, and BRET was followed in real time. Candesartan ko
while they were 2.78 × 105 s−1M−1 and 8.33 × 10−4 s−1, respectively, for AT1R
receptor; BRET, bioluminescence resonance energy transfer; GLuc, Gaussia luc
angiotensin II.real time and high temporal resolution, allowing simple
determination of kinetic ligand parameters. We performed
kinetic experiments on α1AAR in live cells with both GLuc
BRET setups (receptor‒and PM‒ligand BRET). We measured
the dissociation rate constant (koff) of the fluorescent ligand
after its washout: the medium was replaced and supplemented
with unlabeled ligand to prevent rebinding (Fig. 4A). We could
follow the ligand dissociation in both setups. Next, we moni-
tored the association of the fluorescent ligand to the receptor
with real-time measurements (Fig. 4B) and determined the
association rate constant (kon). Kinetic ligand parameters of
unlabeled ligands can be assessed with the help of the
Motulsky–Mahan equation (28). The koff and kon values of the
unlabeled ligand can be calculated by measuring the ligand
binding after simultaneous treatment of the labeled ligand and
the unlabeled ligand in different concentrations. With the
GLuc BRET system we could successfully determine these
parameters of prazosin for α1AAR (Fig. 4B).
We also performed similar studies with AT1R. TAMRA‒
AngII binds AT1R with two different affinities; however, the
proportion of high- and low-affinity states shows a temporal
change upon agonist binding because of the ternary complex
formation with effectors. For the sake of simplicity, we fitted
one site binding curves on the measured points. The koff values
of TAMRA‒AngII differed between receptor‒ligand BRET
and PM‒ligand BRET setups (Fig. 4C), in agreement with the
observation that the N-terminal tagging of AT1R alters its
binding properties. Thereafter, we assessed the kon values of
TAMRA‒AngII (Fig. 4D) and calculated kon and koff for the
unlabeled ligand candesartan in kinetic competitive ligand
binding measurements (Fig. 4E).
Screening of receptor ligands with GLuc BRET
We tested whether our system could be applied for receptor
ligand screening. As a model receptor, we chose the α1AAR, a
major pharmacological target in the treatment of high or low
blood pressure and benign prostate hyperplasia (29). In pre-
liminary experiments, we compared the signal variance in
equilibrium and kinetic binding measurements. From this
viewpoint, the latter seemed to be more advantageous because
of the possibility to apply baseline correction. To statistically
characterize the suitability of our system for high-throughput
screenings, we calculated the Z’-factor statistical parameter
both for receptor‒ligand and PM‒ligand BRET (Fig. 5A) (30).
It was 0.919 and 0.774, respectively, proving that our system
could also be applied in high-throughput screenings. There-
after, we made a test screening with a compound library of 180
compounds (Fig. 5B and Table S1). As positive controls, four
known α1AAR ligands were also tested. We defined those
compounds as hits that induced at least 25% decrease of theLuc–PM, n = 3. D, association kinetics of TAMRA–AngII (1 μM). One phase
04 s−1M−1 for GLuc–AT1R, and kon was 5.27 × 10
3 s−1M−1 for AT1R measured
ultaneously treated with 1 μM TAMRA–AngII and candesartan (Cand) in the
n and koff values were 5.4 × 10
5 s−1M−1 and 1.23 × 10−3 s−1 for GLuc–AT1R,
assessed with GLuc–PM, n = 5. Data are mean ± SD. α1AAR, α1A adrenergic
iferase; PM, plasma membrane; TAMRA‒AngII, red fluorophore–conjugated
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Figure 5. Receptor ligand screening with GLuc BRET. A, statistical validation of the suitability of receptor–ligand BRET and PM–ligand BRET for high-
throughput screenings. After 20-min prazosin (10 μM) or dimethyl sulfoxide pretreatment, 150 nM BODIPY FL–prazosin was added to the cells. BRET
was normalized to vehicle-treatment. Z’-factor values were 0.919 (GLuc–ɑ1AAR) and 0.774 (ɑ1AAR with GLuc–PM), respectively. Results of a representative
experiment with six technical replicates are shown, n = 3. Data are mean ± SD. B, screening for ɑ1AAR ligands. Left panel, receptor–ligand BRET (GLu-
c–ɑ1AAR); right panel, PM–ligand BRET (ɑ1AAR with GLuc–PM). A 180-compound library was tested, and A61603, oxymetazoline, prazosin, and carvedilol
were used as positive controls. After 20-min unlabeled ligand (10 μM) pretreatment, the displacement of 150 nM BODIPY FL–prazosin was assessed. The
screening was performed in duplicate, data are mean ± range. C, competitive ligand binding of the hits using the PM–ligand BRET. Increasing concen-
trations of hits and 375 nM BODIPY FL–prazosin were added to the cells, n = 4. Data are mean ± SD. One site competitive ligand binding curves were fitted,
the Ki values were 1.845 μM (BCC0010913), 121.6 nM (BCC0079473), 86.12 nM (BCC0072526), and 180.4 nM (BCC0061678). D, effects of the hits on calcium
signaling of ɑ1AAR. Cytosolic calcium measurements were performed in Fura-2/AM-loaded cells that overexpressed ɑ1AAR. The cells were first treated with
the hits (10 μM) or vehicle for 1 min, then 100 pM A61603 was used as a stimulus for 3 min. Averages of the signals are shown, data are mean ± SD, n = 3.
The compounds did not induce significant calcium signal but prevented the A61603 effect (two-way ANOVA with Tukey post hoc test, ***p = 0.0001). E,
functional activity of the hits assessed with the SRE-luciferase reporter. After 20-min pretreatment with vehicle or the tested compound (30 μM), 2-h
costimulation with 1 nM A61603 or vehicle was applied. All the hits were antagonists, as they did not induce SRE-luciferase activity but prevented the
A61603 effect, n = 3. Scatter dot plots with bars are shown, data are mean + SD (two-way ANOVA with Tukey post hoc test, performed on the non-
normalized data, ***p = 0.0003). F, the identified new ɑ1AAR ligands antagonize the phenylephrine-induced vasoconstriction. Myography measurements
Detection of ligand binding of unlabeled receptors with GLuc
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Detection of ligand binding of unlabeled receptors with GLucsignal (induced 25% displacement of the tracer ligand). Four
compounds were found as hits (Fig. S5), which were previously
not known to bind to α1AAR. The hits were further charac-
terized. Their KD values were assessed using both ligand
binding setups (Fig. 5C and Fig. S6A). Their functional effects
on α1AAR, a receptor known to trigger phospholipase C–
mediated phosphatidylinositol 4,5-bisphosphate (PIP2) hydro-
lysis and concomitant calcium signaling, were also investi-
gated. All four hits were able to prevent the cytosolic calcium
release induced by the α1AAR agonist A61603 (Fig. 5D).
Similarly, the hits abolished the A61603-induced serum
response element (SRE)-luciferase activation, a reporter of
mitogen-activated protein kinase/extracellular signal-regulated
kinase (MAPK/ERK) signaling and serum response factor ac-
tivity (Fig. 5E). Consistently with these results, they shifted the
A61603 concentration‒response curve of PIP2 cleavage to the
right, representing their competitive α1AAR antagonistic
property (Fig. S6B). Moreover, they alone had no effect on the
vascular tone of mouse aortic rings but antagonized the
vasoconstrictor effect of phenylephrine, a well-known α1
adrenergic receptor agonist (Fig. 5F). These results demon-
strate that our GLuc-based assay could be utilized as a
powerful novel tool for drug screening.
Discussion
Over the last 2 decades, resonance energy transfer–based
methods are emerging in pharmacological studies, which is
particularly true for ligand binding investigations (8, 13).
Time-resolved FRET or BRET (using NanoLuc) was success-
fully adapted to study various receptors, including GPCRs and
receptor tyrosine kinases (9, 11, 12, 31–34). Here we described
a novel ligand binding assay that has the merits of previous
resonance energy transfer–based methods and overcomes
many of their limitations. Like other resonance energy
transfer–based approaches, our system has remarkably low
signal variance, is simple and fast to perform as it lacks labo-
rious experimental steps, and is harmless to health. In addi-
tion, resonance energy transfer–based systems allow ligand
binding kinetics to be monitored in real time with exceptional
temporal resolution. The importance of knowledge of ligand
binding kinetics cannot be emphasized enough, as several
studies have shown that the in vivo action of drugs correlates
much better with kinetic ligand properties, such as kon, koff, or
ligand residence time, than with ligand parameters assessed in
equilibrium. Moreover, our approach is cost-effective, since it
applies the extremely bright Gaussia luciferase that utilizes the
native coelenterazine as a substrate. It should be noted that
inexpensive substrates are available for NanoLuc as well, for
example, coelenterazine h, but the brightness produced is
significantly lower.
Previous resonance energy transfer–based approaches suf-
fered from the need for molecular biological modification of
the protein of interest, since the generation of properlywere performed on murine aortic rings. Data are mean ± SD. Concentration–r
tension was found (one-way ANOVA with Tukey post hoc test), n = 3. α1AAR,
GLuc, Gaussia luciferase; PM, plasma membrane; SRE, serum response elemenfunctioning fusion proteins sometimes requires tremendous
effort and the potential risk of altered function cannot be
completely ruled out even with cautious design and applica-
tion of appropriate controls. Accordingly, several cases of tag-
or even linker-induced functional changes for multiple
receptors have been described, such as endoplasmic reticulum
retention, altered ligand affinity, or modified effector coupling
(12, 24, 25, 35, 36). These examples may be just the tip of the
iceberg, as malfunctioning constructs are not likely to be
published. To examine ligand binding of unlabeled receptors,
we developed a bystander BRET-based approach. Although we
experienced a notable drop in the signal amplitude, the signal
deviation remained low; thus, the separation between signal
and background remained high. We believe that this price is
significantly outweighed by the benefit of being able to
investigate unmodified receptors.
Since only the unmodified receptor and the cell surface–
targeted bioluminescent sensor have to be expressed in a cell
line, our assay can be readily applied to study any cell surface
receptor when a fluorescent ligand is available. We adapted
our system for various GPCRs and non-GPCRs, including
AT1R, AT2R, α1AAR, β2AR, D1R, EGFR, and TfR. We prefer
GLuc to NanoLuc as a bioluminescent donor because of the
higher effect size in our system, but NanoLuc can also be used
based on similar logic. In addition to these proteins, we always
coexpressed dominant-negative dynamin to prevent possible
interference caused by internalization. We found a positive
correlation between the amount of receptor DNA transfected
and the amplitude of the specific BRET signal. Therefore, it
must be noted that the assay is more suitable for measuring
ligand binding of highly expressed receptors, and endogenous
receptors with low copy number may not reach the detection
limit of the method. The system allows the determination of
any ligand binding properties and is particularly useful for
kinetic ligand binding measurements as the assay allows real-
time detection. Theoretically, the signal of the PM‒ligand
BRET setup may be influenced by the change in distance be-
tween the fluorescent ligand-bound receptor and the GLuc‒
PM biosensor. It is known that subtle changes of the bystander
BRET between luciferase-tagged receptors and PM–targeted
fluorescent proteins can also reflect the lateral movement of
the receptor between PM compartments (20, 37). However, we
found no indication that this phenomenon would contribute
significantly to the measured signal in the ligand association
experiments with AT1R or α1AAR. In addition, this issue is
unlikely in dissociation experiments, because alterations in the
localization of the unlabeled receptor are unseen by our assay
after dissociation of the fluorescent ligand.
In high-throughput applications, ligand binding assays offer
several advantages over approaches for assessing signaling
pathways. Receptors are known to activate multiple signaling
pathways, which are not equally modulated by certain ligands
(biased agonists) (38–40). In order to achieve the highestesponse curves were fitted. No significant effect of hit treatment on resting
α1A adrenergic receptor; BRET, bioluminescence resonance energy transfer;
t.
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pathways must be simultaneously examined with distinct as-
says, and different assay conditions are required for agonists
and antagonists. This means that a compound needs to be
screened in several setups, significantly increasing the cost and
the time of the screening. These disadvantages are absent in
ligand binding measurements; a single setup is sufficient to
perform a receptor ligand screen. We proved that our assay is
suitable for high-throughput screenings. As a demonstration,
we screened a compound library of 180 molecules for α1AAR
ligands with our system. We found four previously unknown
α1AAR ligands, which acted as α1AAR antagonists in multiple
functional assays. The relatively high hit rate is consistent with
the observation that a large number of drugs exert off-target
effects through α1AAR, causing orthostatic hypotension and
vertigo (41).
In summary, we have developed a novel ligand binding assay
that allows the determination of ligand binding with low signal
variance and high temporal resolution, providing a powerful
tool for drug characterization and development.
Experimental procedures
Materials
TAMRA‒AngII was purchased from AnaSpec. BODIPY
FL‒prazosin, biotinylated EGF conjugated to Alexa Fluor 488
streptavidin, and Alexa Fluor 488–conjugated human
transferrin were bought from Thermo Scientific. BODIPY FL‒
SKF83566 and BODIPY FL‒(S)-propranolol were from Hel-
loBio. Candesartan and SCH 23390 were purchased from
Tocris. [Sar1,Ile4,Ile8]-angiotensin II was bought from Bachem.
The compound library consisting of randomly selected 180
molecules was from BioAscent. Native coelenterazine and
coelenterazine h were from Regis Technologies. Furimazine
and the Luciferase Assay System were from Promega; Deep-
BlueC (coelenterazine 400a) was from Perkin-Elmer. Fura-2/
AM was from Molecular Probes. ICI118,552 EGF, transferrin,
angiotensin II, A61603, prazosin, and otherwise not stated
materials were from Sigma-Aldrich.
Plasmid constructs
The plasmid constructs coding the rat AT1R, α1AAR, β2AR,
EGFR, and the PM PIP2 BRET biosensor (L10‒Venus‒T2A‒
PLCδ1-PH‒SLuc) were described (23, 42, 43). SRE-luciferase,
containing the SRE promoter region fused with the coding
sequence of firefly luciferase, was from Promega. The cDNA of
human D1R and hemagglutinin‒dynamin2A‒K44A (DN-Dyn)
were kind gifts from Dr Marc G. Caron and Dr Kazuhisa
Nakayama, respectively. The coding sequence of untagged rat
AT2R without the untranslated regions was polymerase chain
reaction (PCR) amplified and inserted into pEYFP-N1 by
replacing YFP. The C-terminal GFP-tag of TfR‒GFP (kindly
provided by Dr Tamás Balla) was replaced by hemagglutinin-
tag to create TfR‒hemagglutinin. To generate GLuc‒PM, the
DNA sequence of Gaussia luciferase signal peptide followed by
GLucM23 (humanized GLuc harboring the K50E, M60L,
V113D, M127I, and G184D mutations (16)) fused to the10 J. Biol. Chem. (2021) 296 100366transmembrane domain of platelet derived growth factor (PM)
with a flexible (GGGSGGGSRSGGGSGGGSGGGS) linker was
gBlock synthetized and was inserted into pcDNA3.1 vector. To
create NanoLuc‒PM, the coding sequence of NanoLuc N-
terminally fused with the secretion signal peptide of
interleukin-6 was gBlock synthetized and the signal peptide-
fused GLucM23 was replaced with that in GLuc‒PM. N-
terminally GLuc- or NanoLuc-tagged AT1Rs harboring a short
linker (GGGSGGGS) were generated by PCR amplification of
the sequence of rat AT1R to replace PM in GLuc‒PM and
NanoLuc‒PM, respectively. A similar strategy was used to
generate GLuc‒α1AAR. To create GLuc‒PM‒Venus and
NanoLuc‒PM‒Venus, GLuc‒PM and NanoLuc‒PM were
PCR amplified without stop codons and were inserted into
pVenus-N1 vector before the sequence of monomeric Venus.Cell culture and transfection
HEK 293T cells (from American Type Culture Collection:
CRL-3216) were cultured in Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with 10% fetal bovine serum and
100 IU/ml penicillin/streptomycin. To visualize the cellular
localization of the probes, the cells were plated on coverslips on
the day before transfection, and the adherent cells were trans-
fected with the calcium phosphate precipitation method: for
each well (24-well plate), 1 μg plasmid DNA was diluted in 45 μl
distilled water, to this 5 μl 2.5 M CaCl2 was rapidly added, then
50 μl 2× HEBS (Hepes-buffered salt solution, containing
274 mM NaCl, 15 mM glucose, 42 mM Hepes, 10 mM KCl,
1.4 mM Na2HPO4, pH 7.1) was added slowly, and the solution
was added dropwise to the culture medium (1 ml) of cells. The
amounts and volumes for calcium phosphate precipitation were
proportionally increased or decreased for wells with bigger or
smaller surfaces. For cytosolic calcium measurements, the cells
were plated on IBIDI μ-Slide 8-well plates and a similar pro-
cedure was applied. Otherwise, the transfections were performed
in suspension using the calcium phosphate precipitation
method, and the cells were plated on white 96-well plates.
Mixture volumes were multiplied by the number of wells
transfected, plasmid DNAs were diluted in 9 μl distillated water,
1 μl 2.5 M CaCl2, and 10 μl 2× HEBS per well, as described
above, and the transfection solution was added dropwise to HEK
293T cells suspended in supplemented DMEM (8 × 104 cells in
200 μl of medium per well). A volume of 200 μl of the mixture
was seeded on each well. For receptor‒ligand BRET measure-
ments, the plasmid DNA of luciferase-tagged receptor and DN-
Dyn were transfected in 1:4 ratio (0.05 and 0.2 μg per well). In
the PM‒ligand BRET measurements, the receptor:luciferase‒
PM:DN-Dyn plasmid DNA ratio was 20:1:5 (0.2, 0.01, and
0.05 μg per well), unless otherwise stated.
Bioluminescent and fluorescent image acquisition
For live cell image acquisition, coverslips were held in
Chamlide magnetic chambers in Hanks' balanced salt solution
media. Images were collected with a Nikon Ti2 inverted mi-
croscope with a Hamamatsu ORCA Flash 4 V3 sCMOS
camera using a 100× objective. Five micromolar coelenterazine
Detection of ligand binding of unlabeled receptors with GLuch and 5 μM native coelenterazine were used as substrates for
NanoLuc and GLuc, respectively. Luminescence was detected
by applying 10-s exposure time with 4× averaging. Fluores-
cence was recorded by excitating at 488 nm laser, and emission
was detected using a Quad band filter. The images were
individually processed, looking up tables were adjusted in each
image distinctively to achieve high contrast.
Luciferase activity measurements
The emission spectra of GLuc‒PM and NanoLuc‒PM were
detected using a Thermo Scientific Varioskan Flash multimode
plate reader (spectral scanning mode using a monochromator).
Since the peak total luminescence of GLuc surpassed the
detection limit of the Varioskan Flash plate reader, fluores-
cence and luminescence intensities of GLuc‒PM‒Venus or
NanoLuc‒PM‒Venus were measured with a BMG Labtech
CLARIOstar microplate reader. Venus fluorescence was
assessed by exciting at 497/15 nm and measuring emission at
540/20 nm. Total luminescence was measured without filter
(gain 1100, integration time 0.2 s).
Bioluminescence resonance energy transfer measurements
All measurements were performed on adherent cells. On the
day after transfection, the cells werewashed and themediumwas
changed to modified Krebs–Ringer medium (120 mM NaCl,
10 mM glucose, 10 mMNa-Hepes, 4.7 mMKCl, 1.2 mMCaCl2,
0.7 mM MgSO4, pH 7.4). Equilibrium binding studies were
performed after 2-h incubation of labeled and unlabeled ligands
at roomtemperature. Incubationsweremade on ice forβ2ARand
D1R binding measurements. Luminescence was measured using
a Varioskan Flash multimode plate reader at 27 C. For Nano-
BRET measurements, light intensities were measured with 460/
20- and 610/60-nm bandpass filters after addition of 5 μM coe-
lenterazine h. GLuc BRET measurements were performed after
treatment with 5 μM native coelenterazine, TAMRA‒AngII
binding was monitored using 480/20- and 610/60-nm filters,
whereas 480/20- and 530/20-nm filters were applied in BRET
measurements with green-emitting (BODIPY FL- or Alexa Fluor
488–conjugated) fluorescent ligands.
To assess Koff of fluorescent ligands, the ligands were pre-
incubated with the cells for 15 min. Thereafter, the cells were
washed and the medium was replaced with media containing
coelenterazine and unlabeled ligand (10 μM candesartan for
AT1R, 10 μM prazosin for α1AAR) to prevent rebinding. To
determine the maximal signal, control cells were treated with
labeled ligand and coelenterazine, but no unlabeled ligand was
added. Basal BRET was assessed in cells treated with no labeled
ligand. For analysis, basal BRET was always subtracted. For Kon
measurements of fluorescent ligands, cells were treated with
coelenterazine, baseline BRETwasmonitored for 3min, and then
the cells were treated with fluorescent ligands. Kinetic parameters
of unlabeled ligandsweremeasured similarly.After baselineBRET
assessment, the cellswere treated simultaneouslywith fluorescent
ligand and increasing concentrations of unlabeled ligand.
PM PIP2 levels were monitored using a PIP2 BRET biosensor
(L10–Venus–T2A–PLCδ1-PH–SLuc) (23). Bystander BRETwas measured between Super Renilla luciferase-tagged PLCδ1-
PH (the PIP2-binding domain of PLCδ1) and PM–targeted
Venus in cells coexpressing PIP2 BRET biosensor and α1AAR.
The BRET ratio decreased upon treatment with α1AAR agonist,
which reflects the phospholipase C–mediated PIP2 cleavage. A
5-min pretreatment with the hit compounds (10 μM) was
applied, then the cells were stimulated with increasing con-
centrations of α1AAR agonist A61603. First, the agonist-
induced BRET change was determined (the BRET ratio after
pretreatment was subtracted from the average of the BRET
ratios measured in the first 5 min after stimulation), then the
BRET signal was expressed in the percent of the 10 μM
A61603-induced BRET change in vehicle-pretreated cells.
The screening was performed using a compound library
harboring 180 compounds (Table S1). The compounds were
randomly recruited from the BioAscent library of approximately
1.2 × 106 molecules. To obtain a better signal-to-noise ratio, 1.75
timesmore cells (1.4 × 105)were seededperwell on 96-well plates.
Outerwells of plateswerenot used to rule out the edge effect; only
the inner 60 wells were measured. Before the measurements, the
cells were pretreated with the compounds for 20 min in 10 μM
(which was diluted to 6 μMafter substrate and ligand treatment).
After addition of coelenterazine, baseline BRET was determined
for 5 min, then the cells were stimulated with 150 nM BODIPY
FL–prazosin or vehicle. The same experimental procedure was
used for Z’-factor assessment, BRET was monitored in six wells
per conditionon96-well plates, and theZ’-factorwas calculated as
previously described (30).Cytosolic calcium concentration measurements
Adherent HEK 293T cells overexpressing α1AAR were
treated with 200 μM sulfinpyrazone and loaded with the
ratiometric fluorescent dye Fura-2/AM (2 μM, 45 min). Single-
cell calcium measurements were performed using an inverted
microscope (Axio Observer, Zeiss) equipped with a 40× oil
immersion objective (Fluar, Zeiss) and a Cascade II camera
(Photometrics). Excitation wavelengths were set by a random
access monochromator connected to a xenon arc lamp (Del-
taRAM, Photon Technology International). For ratiometric
measurements of Fura-2 excitation wavelengths of 340 and
380 nm were selected combined with a 505-nm dichroic filter
and a 525/36-nm emission filter set. Data acquisition was
performed by the MetaFluor (Molecular Devices) software.
Images were acquired every 5 s. After a control period (1 min),
cells were treated with vehicle (dimethyl sulfoxide) or test
compound (10 μM), then the cells were stimulated with 100
pM A61603 for 3 min. Image analysis was performed with
ImageJ software; the ratio of fluorescent intensities measured
at 340 and 380 nm excitations was taken. About 150 to 200
regions of interest representing individual cells from each
experiment and each treatment were measured, and fluoro-
metric ratios were normalized to the control period.
SRE-luciferase activity measurement
HEK 293T cells were transiently transfected with SRE-
luciferase and receptor plasmids in suspension and wereJ. Biol. Chem. (2021) 296 100366 11
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serum starved for 2 h by replacing the media to DMEM
containing 1% penicillin/streptomycin and 1% bovine serum
albumin. Then the medium was changed to modified Krebs–
Ringer medium, and the cells were pretreated with vehicle or
the investigated compounds (30 μM) for 20 min, then 2-h
costimulation with 1 nM A61603 or vehicle was applied at
37 C. Then the cells were plated on ice and were lysed with
passive lysis buffer (Promega). After 20-min rocking at room
temperature, the Luciferase Assay System (Promega) substrate
was added and luminescence was measured with a Thermo
Scientific Varioskan Flash multimode plate reader at 27 C.
Wire myography
Myography experiments were performed as described (44).
Male C57BL/6 mice were terminated by cervical dislocation,
and the vascular system was perfused through the left ventricle
and a right atrial slit with Kreb’s solution containing 119 mM
NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.17 mM MgSO4, 20 mM
NaHCO3, 1.18 mM KH2PO4, 0.027 mM EDTA, and 10 mM
glucose (pH 7.4). Abdominal aortas were removed and placed
into Kreb’s solution. Aortic rings (3–4 mm), five segments from
each animal, were mounted onto a multichamber isometric
myograph system (Danish Myo Technology). The organ
chambers were filled with Kreb’s solution kept at 37 C and
bubbled with carbogen gas (5% CO2 and 95% O2). Recording of
isometric tension was performed with the Powerlab data
acquisition system and the LabChart evaluation program
(ADInstruments). The segments were allowed to equilibrate for
30 to 40 min, and the resting tension was adjusted to 10 mN.
First, contractions were elicited by hyperkalemic (124 mM)
solution for 1 min. Endothelial integrity was tested with the
vasodilatory response by acetylcholine (100 nM) after phenyl-
ephrine precontraction (100 nM). Before compound treat-
ments, a 3-min KCl reference contraction was induced, then
resting tension was adjusted again with washing steps. Treat-
ments with the hit compounds (10 μM)were applied for 15min.
Next, phenylephrine was administered in cumulative concen-
trations (10 nM–100 μM). Vasoconstrictor responses were
expressed as percentages of the 3-min KCl-induced reference
contraction. All experimental procedures were reviewed and
approved by the Animal Care Committee of Semmelweis
University (Budapest, Hungary).
Mathematical and statistical analysis
Data plotting, statistical analysis, and curve fittings were
performed with GraphPad Prism 9 software. One or two
site-specific binding curves were fitted on the specific signal
points of equilibrium binding measurements. With the use of
the determined KD values, total (one site or two site) and
nonspecific binding were also fitted. One or two site compe-
tition binding curves were fitted in the case of equilibrium
competitive ligand binding measurements. Ki values were
calculated with the Cheng–Prusoff equation (45). To deter-
mine labeled ligand–receptor Koff in measurements of
Figure 4, one phase exponential decay curves were fitted.12 J. Biol. Chem. (2021) 296 100366Thereafter, the “association kinetic (one ligand concentration)”
equation was used to calculate labeled ligand–receptor Kon
with constrained Koff and Bmax (maximum specific binding,
determined in equilibrium binding measurements). Koff and
Kon values of the unlabeled ligand–receptor interaction were
determined with the “Kinetics of competitive binding”
(Motulsky–Mahan) equation (28). To calculate τ, one phase
association curves were fitted. The results of curve fits for
ligand binding experiments in the main figures are summa-
rized in Table S2.
For statistical comparison, unpaired two-tailed t test and
one-way or two-way ANOVA with Tukey post hoc test were
applied.
Data availability
GLuc‒PM and NanoLuc‒PM biosensors will be available
from Addgene after publication.
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